SHAREHOLDERS

Why invest in AB Science.

Discover AB Science’s strengths, programmes and prospects.

High unmet medical need and strong market potential
  • The indications pursued are all high unmet medical needs
  • The indications pursued combined both blockbuster potential diseases or are orphan diseases
Unique mechanism of action
  • Lead compound: Masitinib, kinase inhibitor selectively targeting the innate immune system through mast cells and macrophages/microglia
  • New compound: AB8939, next generation, synthetic microtubule destabilizer able to overcome multidrug resistance
Strong IP position
  • IP 100% owned by AB Science

STOCK MARKET INFORMATION

Shareholder information.

Find stock market data and useful information for shareholders.

Share price

Stock exchange: Euronext
PEA / SRD eligibility: Yes / Yes
ISIN code: FR0010557264

ICB classification:
– Industry : 4000, Health Care
– SupSector : 4500, Health Care
– Sector : 4570, Pharmaceuticals & Biotechnology
– SubSector : 4577, Pharmaceuticals